aibio
Listings ·
Immutep Ltd regains Nasdaq bid price compliance after ADS ratio change
Nasdaq confirmed on October 12, 2026 that the matter is closed. The company changed its ADS ratio from 10 to 200 ordinary shares effective September 28, 2026.
IMM Immutep Ltd
Immutep (IMM) news
Latest Immutep news
- Financings
Immutep's FY2026 loss widens 29.1% after TACTI-004 lung cancer trial is discontinued
Loss after tax attributable to owners was 79,304,563 for the year ended 30 June 2026, up from 61,434,165. Revenue included $14.6 million from licensing partner Dr Reddy's.
What Immutep does
Immutep Ltd. is a late-stage biotechnology company developing LAG-3 related immunotherapies for cancer and autoimmune disease. Its lead clinical candidate is eftilagimod alfa, known as efti or IMP321, a soluble LAG-3 fusion protein that the company describes as a first-in-class antigen-presenting cell agonist. In March 2026, following a planned interim futility analysis, Immutep discontinued TACTI-004, its registrational Phase III trial of efti with an anti-PD-1 therapy and chemotherapy in first-line non-small cell lung cancer, and began an orderly wind-down. The company says it completed the randomized Phase IIb TACTI-003 trial of efti in head and neck squamous cell carcinoma and received positive, constructive feedback from the FDA on further development. During fiscal 2026 it licensed efti to Dr. Reddy's Laboratories for all markets outside what it calls the Immutep Territory, which includes the United States, Canada, Europe, Japan and Greater China. The license with Novartis for IMP701, also called ieramilimab, was terminated, and the asset is being transferred back to Immutep. Immutep also develops IMP761, an agonist of LAG-3 for autoimmune disease. It employed 46 people as of June 30, 2026, and relies on outside contractors and consultants for manufacturing and clinical trials.
| Product or program | What it is | Stage |
|---|---|---|
| Eftilagimod alfa (efti, IMP321) | Lead LAG-3 immunotherapy for cancers, licensed to Dr. Reddy's outside the Immutep Territory | Phase IIb completed in head and neck cancer; registrational Phase III discontinued March 2026 |
| IMP701 (ieramilimab) | LAG-3 asset whose Novartis license was terminated, returning to Immutep | clinical-stage |
| IMP761 | LAG-3 agonist for autoimmune disease | clinical-stage |
| IMP731 | LAG-3 asset previously licensed to a major pharmaceutical company and returned to Immutep | clinical-stage |
Immutep annual financials
| Line | FY ended Jun 30, 2025 | FY ended Jun 30, 2024 |
|---|---|---|
| Revenue | A$10.3 million | A$7.8 million |
| Research and development | A$49.8 million | A$31.5 million |
| Net income (loss) | -A$61.4 million | -A$42.7 million |
| Cash from operations | -A$62.0 million | -A$34.8 million |
| Cash and equivalents | A$67.4 million | A$161.8 million |
| Short-term investments | A$62.3 million | A$20.1 million |
Questions about Immutep
What is the ticker symbol of Immutep?
Immutep Ltd trades under the ticker IMM on ASX.
Where is Immutep listed?
Immutep Ltd is listed on ASX. Our directory also records these other listings: GETTEX:YP1B; LSX:A2H81H; NASDAQ:IMMP; OTC:PRRUF.
What is the SEC CIK of Immutep?
The SEC Central Index Key (CIK) for Immutep Ltd is 1506184. Its filings are on SEC EDGAR.
How many shares does Immutep have outstanding?
1,460,389,575 shares as of 2025-06-30, per the cover page of its 20-F filed 2025-10-24.
Which country or territory is Immutep listed under?
Our directory records Immutep Ltd under Australia.
What does Immutep do?
Our directory classifies Immutep Ltd as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Immutep?
The ISIN recorded for Immutep Ltd is AU000000IMM6.
Does aibio.space cover Immutep?
aibio.space lists Immutep Ltd among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Immutep incorporated?
SEC records list its state or country of incorporation as C3.
What does Immutep develop?
Immutep Ltd. is a late-stage biotechnology company developing LAG-3 related immunotherapies for cancer and autoimmune disease. Its lead clinical candidate is eftilagimod alfa, known as efti or IMP321, a soluble LAG-3 fusion protein that the company describes as a first-in-class antigen-presenting cell agonist.
What is Eftilagimod alfa (efti, IMP321) from Immutep?
Eftilagimod alfa (efti, IMP321): Lead LAG-3 immunotherapy for cancers, licensed to Dr. Reddy's outside the Immutep Territory Stage: Phase IIb completed in head and neck cancer; registrational Phase III discontinued March 2026.
What is IMP701 (ieramilimab) from Immutep?
IMP701 (ieramilimab): LAG-3 asset whose Novartis license was terminated, returning to Immutep Stage: clinical-stage.
What is the latest Immutep (IMM) stock news?
Our latest story on Immutep, dated Oct 14, 2026: "Immutep Ltd regains Nasdaq bid price compliance after ADS ratio change". Nasdaq confirmed on October 12, 2026 that the matter is closed. The company changed its ADS ratio from 10 to 200 ordinary shares effective September 28, 2026. Source.
What is Immutep's latest stock offering or financing news?
Our latest financing story, dated Sep 2, 2026: "Immutep's FY2026 loss widens 29.1% after TACTI-004 lung cancer trial is discontinued". Loss after tax attributable to owners was 79,304,563 for the year ended 30 June 2026, up from 61,434,165. Revenue included $14.6 million from licensing partner Dr Reddy's. Source.
How long will Immutep's cash last?
From our story of Sep 2, 2026: The chairman's letter says the company expects a cash runway well into the first half of calendar 2028. Source.
Investor discussion: Immutep
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Legal
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 20-F. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
- Financings
Reported a financing. SEC Form 6-K. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
- Financings
Reported a financing. SEC Form 6-K. Source
Stock chart
SEC filings and registration
- SEC name
- IMMUTEP Ltd
- CIK
- 1506184
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- IMMP (Nasdaq), PRRUF (OTC)
- State or country of incorporation
- C3
- Fiscal year ends
- June 30
- Filer category
- Accelerated filer
- Business address
- LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE, SYDNEY,, Australia, NSW 2000
- Phone
- 612 8315 7003
- Shares outstanding
- 1,460,389,575 as of 2025-06-30 (20-F filed 2025-10-24)
- Former names
- Prima BioMed Ltd
Recent filings
Listing details
- Company
- Immutep Ltd
- Ticker
- IMM
- Listing
- ASX
- Country or territory
- Australia
- Business scope
- Biotechnology
- ISIN
- AU000000IMM6
- Other listed symbols
- GETTEX:YP1B; LSX:A2H81H; NASDAQ:IMMP; OTC:PRRUF
- Last quote in directory
- 2026-10-22
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction